BR112013015001A8 - peptídeo antitumor isolado ou sintético, composição farmacêutica, métodos para inibir o crescimento de tumor, e para tratar um tumor ou câncer, e, uso de um peptídeo - Google Patents

peptídeo antitumor isolado ou sintético, composição farmacêutica, métodos para inibir o crescimento de tumor, e para tratar um tumor ou câncer, e, uso de um peptídeo Download PDF

Info

Publication number
BR112013015001A8
BR112013015001A8 BR112013015001A BR112013015001A BR112013015001A8 BR 112013015001 A8 BR112013015001 A8 BR 112013015001A8 BR 112013015001 A BR112013015001 A BR 112013015001A BR 112013015001 A BR112013015001 A BR 112013015001A BR 112013015001 A8 BR112013015001 A8 BR 112013015001A8
Authority
BR
Brazil
Prior art keywords
peptide
cancer
isolated
treating
methods
Prior art date
Application number
BR112013015001A
Other languages
English (en)
Other versions
BR112013015001B1 (pt
BR112013015001A2 (pt
Inventor
Rodolpho Raja Gabaglia Travassos Luiz (35%)
Original Assignee
Recepta Biopharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recepta Biopharma S A filed Critical Recepta Biopharma S A
Publication of BR112013015001A2 publication Critical patent/BR112013015001A2/pt
Publication of BR112013015001A8 publication Critical patent/BR112013015001A8/pt
Publication of BR112013015001B1 publication Critical patent/BR112013015001B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/10—Bryophyta (mosses)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112013015001-7A 2010-12-14 2011-12-14 Peptídeo antitumor isolado ou sintético, composição farmacêutica, e, usos de um peptídeo BR112013015001B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42285610P 2010-12-14 2010-12-14
US61/422,856 2010-12-14
PCT/IB2011/003053 WO2012080822A2 (en) 2010-12-14 2011-12-14 Antitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to napi2b transporter

Publications (3)

Publication Number Publication Date
BR112013015001A2 BR112013015001A2 (pt) 2017-12-19
BR112013015001A8 true BR112013015001A8 (pt) 2018-04-17
BR112013015001B1 BR112013015001B1 (pt) 2021-10-13

Family

ID=46245158

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013015001-7A BR112013015001B1 (pt) 2010-12-14 2011-12-14 Peptídeo antitumor isolado ou sintético, composição farmacêutica, e, usos de um peptídeo

Country Status (8)

Country Link
US (2) US9193797B2 (pt)
EP (1) EP2654769B1 (pt)
JP (1) JP6087289B2 (pt)
BR (1) BR112013015001B1 (pt)
CO (1) CO6721014A2 (pt)
ES (1) ES2804476T3 (pt)
PT (1) PT2654769T (pt)
WO (1) WO2012080822A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2929565A1 (en) * 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CN105491524B (zh) * 2015-12-11 2019-04-26 小米科技有限责任公司 一种确定目标便携设备位置的方法和装置
WO2019006529A2 (en) * 2017-07-01 2019-01-10 Recepta Biopharma S A IMMUNOMODULATORY PEPTIDES AND MODULATION METHODS
CA3075798A1 (en) * 2017-09-20 2019-03-28 Mersana Therapeutics, Inc. Compositions and methods for predicting response to napi2b-targeted therapy
CN116514926B (zh) * 2023-06-25 2023-08-29 烟台药物研究所 一种抗肿瘤阳离子两亲肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
AU684348B2 (en) * 1994-06-07 1997-12-11 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and adioactive therapeutic agent containing the peptide
US6689753B1 (en) 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
JP2007534631A (ja) * 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
EP2250201B1 (en) * 2008-01-29 2014-04-30 Ludwig Institute for Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

Also Published As

Publication number Publication date
ES2804476T3 (es) 2021-02-08
JP6087289B2 (ja) 2017-03-01
PT2654769T (pt) 2020-07-16
US9193797B2 (en) 2015-11-24
BR112013015001B1 (pt) 2021-10-13
BR112013015001A2 (pt) 2017-12-19
CO6721014A2 (es) 2013-07-31
EP2654769A4 (en) 2017-10-25
JP2014510699A (ja) 2014-05-01
US9896512B2 (en) 2018-02-20
WO2012080822A2 (en) 2012-06-21
WO2012080822A9 (en) 2016-08-11
US20130315902A1 (en) 2013-11-28
EP2654769B1 (en) 2020-04-15
EP2654769A2 (en) 2013-10-30
US20160108132A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
BR112015004547A2 (pt) compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer
BR112012018947A8 (pt) composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
BR112015003757A2 (pt) anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BR112012018943A8 (pt) medicamento e método para o tratamento e/ou prevenção de um câncer
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
EP2532364A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
PL3351630T3 (pl) Kompozycja farmaceutyczna zawierająca przeciwciała przeciwko CAPRIN-1 do leczenia nowotworu i/lub zapobiegania nowotworowi
CL2014000543A1 (es) Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
BR112015001830A2 (pt) composto, uso de um composto, método para o tratamento ou profilaxia de câncer e invenção
BR112014015003A2 (pt) composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral
BR112014005091A2 (pt) composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
BR112014030416A2 (pt) composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção.
BRPI0920759A2 (pt) composição dos peptídeos associados a tumor e vacina anticâncer relacionada para o tratamento do glioblas-toma(gbm) e outros tipos de câncer
PL2740793T3 (pl) Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
BR112015007866A2 (pt) combinação de opióides e fármacos anticancerígenos para o tratamento do câncer.
BR112014003681A2 (pt) composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
EP2532680A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
BR112014032053A2 (pt) composto, composição farmacêutica, utilização de um composto, método para o tratamento de câncer e invenção
BR112014029404A2 (pt) compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção
BR112015000649A2 (pt) compostos, composição farmacêutica, uso de um composto, método para tratar ou melhorar câncer e invenção
EP2617413A4 (en) NANIUM DERIVED FROM A TUMOR TISSUE AND CANCER VACCINE THEREFOR
BR112012030927A2 (pt) fosfaplatinas e seu uso para o tratamento de cânceres
BR112013015001A8 (pt) peptídeo antitumor isolado ou sintético, composição farmacêutica, métodos para inibir o crescimento de tumor, e para tratar um tumor ou câncer, e, uso de um peptídeo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/12/2011, OBSERVADAS AS CONDICOES LEGAIS.